Welcome to the Life Sciences Sector!

The Life Sciences Sector provides LES members in all areas of the life sciences industry, including but not limited to the Pharmaceutical, Biotech, BioMedical Devices, and Diagnostics & Genomics segments, with a place to network, share common experiences and learn from one another.

From the Life Sciences Sector

If you are here, then you most likely are interested to get plugged into what your LES Life Sciences Sector is up to and for that we thank you!

LES is a volunteer organization, and each of us is just like you - seeking how we might learn more about our industry and profession via education and networking As a member, you can be proud that the LSS is leading the charge within LES to raise the bar of quality and quantity of educational content and networking opportunities. And with your help, we hope to continue to make improvements.

There are many ways you can get involved. One of the easiest may be to participate in a workshop at an upcoming meeting. 

While you are here, you might also wish to check out some of our other stuff. Under the link "LS Education and Content", you will find an excellent series of proprietary life science specific articles, written by some of the most thought provoking commentators on our industry. Under "LS News" you will find the latest of our quarterly email blasts to the LES Life Sciences Sector members.

In closing, we invite you to be active in your sector. If you have an idea or would like to volunteer, please contact the sector leaders.

LES Life Sciences Webcasts Now Available

Learn more about the future direction of the Life Sciences industry in the U.S. by accessing these key sessions from the 2012 LES (USA & Canada) Spring Meeting:

Licensing as a Source of Innovation
Genzyme CEO David Meeker

Plenary Panel:  Licensing to Solve the Innovation Gap
Featuring:
Daniel Behr, Access BridgeGap Ventures
Jeff Elton, Accenture
Robert  Langer, MIT

These sessions are available to all LES members worldwide for the preferred rate of $159.00 for both sessions, or $100.00 for each session.

To purchase your session and download the content, visit:

https://live.blueskybroadcast.com/bsb/client/CL_DEFAULT.asp?Client=691019&title=Home

Global BioPharma Royalty Rates and Deal Terms Survey

2012 Survey Highlights

  • A total of 120 completed surveys were incorporated into the final Global BioPharma Survey Report. 
  • Of those who responded, 31% were from pharmaceutical companies, 22% were from biotech companies, 9% were from academic institutions, 6% were from government, and 32% were from other organizations.
  • The survey covered assets at all stages of development and the report offers a wealth of information on early stage programs. In all, 24% of the deals addressed assets in the discovery phase and another 16% covered programs that were on an IND track but had not yet been filed. 
  • Approximately 65% of the deals were considered “Global” in scope.
  • The survey covered assets at all stages of development and the report offers a wealth of information on early stage programs. In all, 24% of the deals addressed assets in the discovery phase and another 16% covered programs that were on an IND track but had not yet been filed. 

Read the press release here. The full survey is available to LES members, please login for access. 

Click here to access information regarding the 2009 Global BioPharma Royalty Rates and Deal Terms Survey.

Click here to access information regarding the 2008 Global BioPharma Royalty Rates and Deal Terms Survey.

LESI WORKING GROUPS

Life Sciences

Contact LS

Ideas? Complaints? Questions? Want to volunteer? Use this link to send us your thoughts.

LES Community Conversations

Learn and network with your peers without ever having to leave your office.
Read more...

LES 2013 Annual Meeting